Champions Oncology Management
Management criteria checks 4/4
Champions Oncology's CEO is Ronnie Morris, appointed in Jan 2017, has a tenure of 7.25 years. total yearly compensation is $600.00K, comprised of 66.7% salary and 33.3% bonuses, including company stock and options. directly owns 6.32% of the company’s shares, worth $4.35M. The average tenure of the management team and the board of directors is 2.6 years and 12.8 years respectively.
Key information
Ronnie Morris
Chief executive officer
US$600.0k
Total compensation
| CEO salary percentage | 66.7% |
| CEO tenure | 7.3yrs |
| CEO ownership | 6.3% |
| Management average tenure | 2.6yrs |
| Board average tenure | 12.8yrs |
Recent management updates
Recent updates
Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?
Sep 28
Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M
Jul 21We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation
Oct 14We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth
Jun 21Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?
Apr 09Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation
Mar 19The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?
Mar 02Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?
Feb 04Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?
Jan 14Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares
Dec 19Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results
Dec 16
Champions Oncology beats on revenue
Dec 14Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jan 31 2024 | n/a | n/a | -US$10m |
| Oct 31 2023 | n/a | n/a | -US$10m |
| Jul 31 2023 | n/a | n/a | -US$8m |
| Apr 30 2023 | US$600k | US$400k | -US$5m |
| Jan 31 2023 | n/a | n/a | -US$3m |
| Oct 31 2022 | n/a | n/a | US$108k |
| Jul 31 2022 | n/a | n/a | US$401k |
| Apr 30 2022 | US$800k | US$400k | US$548k |
| Jan 31 2022 | n/a | n/a | US$219k |
| Oct 31 2021 | n/a | n/a | US$391k |
| Jul 31 2021 | n/a | n/a | US$115k |
| Apr 30 2021 | US$775k | US$375k | US$362k |
| Jan 31 2021 | n/a | n/a | -US$1m |
| Oct 31 2020 | n/a | n/a | -US$2m |
| Jul 31 2020 | n/a | n/a | -US$1m |
| Apr 30 2020 | US$1m | US$394k | -US$2m |
| Jan 31 2020 | n/a | n/a | -US$181k |
| Oct 31 2019 | n/a | n/a | -US$956k |
| Jul 31 2019 | n/a | n/a | -US$995k |
| Apr 30 2019 | US$146k | US$146k | US$128k |
| Jan 31 2019 | n/a | n/a | -US$251k |
| Oct 31 2018 | n/a | n/a | US$42k |
| Jul 31 2018 | n/a | n/a | -US$320k |
| Apr 30 2018 | US$244k | n/a | -US$1m |
| Jan 31 2018 | n/a | n/a | -US$3m |
| Oct 31 2017 | n/a | n/a | -US$5m |
| Jul 31 2017 | n/a | n/a | -US$5m |
| Apr 30 2017 | US$305k | n/a | -US$7m |
Compensation vs Market: Ronnie's total compensation ($USD600.00K) is about average for companies of similar size in the US market ($USD681.24K).
Compensation vs Earnings: Ronnie's compensation has been consistent with company performance over the past year.
CEO
Ronnie Morris (57 yo)
7.3yrs
Tenure
US$600,000
Compensation
Dr. Ronnie Morris, M.D. has been Chief Executive Officer at Champions Oncology, Inc. since January 31, 2017. Dr. Morris previously served as the President and a Director of Champions Oncology, Inc. from Oc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.3yrs | US$600.00k | 6.32% $ 4.4m | |
| Chief Financial Officer | 6.9yrs | US$294.30k | 0.041% $ 27.9k | |
| President | less than a year | no data | no data | |
| Chief Operating Officer | less than a year | no data | no data | |
| Vice President of Technology | 3.9yrs | no data | no data | |
| VP of Global Marketing | no data | no data | no data | |
| Executive Vice President of Global Laboratory Operations | 2.6yrs | no data | no data | |
| Chief Commercial Officer | no data | no data | no data | |
| Executive Vice President of Global Scientific Operations | 2.6yrs | no data | no data | |
| Executive Vice President of Commercial | less than a year | no data | no data |
2.6yrs
Average Tenure
Experienced Management: CSBR's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 13.5yrs | US$600.00k | 6.32% $ 4.4m | |
| Independent Director | 12.8yrs | US$88.42k | 0.22% $ 152.0k | |
| Independent Chairman of the Board | 13.5yrs | US$110.53k | 6.3% $ 4.3m | |
| Independent Lead Director | 16.7yrs | US$82.89k | 5.64% $ 3.9m | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 11.1yrs | US$81.05k | 1.46% $ 1.0m | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 8yrs | US$82.89k | 0.11% $ 74.1k | |
| Board Observer | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 3.2yrs | US$78.94k | 0% $ 0 |
12.8yrs
Average Tenure
57.5yo
Average Age
Experienced Board: CSBR's board of directors are seasoned and experienced ( 12.8 years average tenure).